The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2017 | Upfront ASCT for newly diagnosed multiple myeloma: double vs. single transplant
The use of frontline autologous stem cell transplantation (ASCT) for newly diagnosed multiple myeloma (MM) has been questioned due to the development of new drugs. However, as explained here by Laurent Garderet, MD, PhD, of Saint Antoine Hospital, Paris, France, it is thought that ASCT should not be delayed. Furthermore, Dr Garderet discusses whether double vs. single ASCT is more beneficial for patients, and what the results of the data for this, presented at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA, may mean for the clinical management of MM.
